503b bulks list
FDA's 503B Exclusion Will Raise Semaglutide Copays By 2026
One hundred patients could end up paying an extra $200-$300 a month because the FDA removed semaglutide, tirzepatide and liraglutide from the 503B bulks list, and that will raise copays by 2026. The exclusion eliminates bulk pricing that has kept out-of-pocket costs low for chronic weight-loss therapy. Medical Disclaimer: